133991-62-5

Basic information

• Product Name: 17α-[(ethoxycarbonyl)oxy]-11β-hydroxy-3-oxoandrosta-1,4-diene-17β-carboxylic ethoxycarboxylic anhydride
• CAS NO: 133991-62-5
• Molecular Weight: 490.551
• Mol File: 133991-62-5.mol

Chemical Properties

• Melting Point: 200 - 205°C
• CAS DataBase Reference: 17α-[(ethoxycarbonyl)oxy]-11β-hydroxy-3-oxoandrosta-1,4-diene-17β-carboxylic ethoxycarboxylic anhydride(CAS DataBase Reference)
• NIST Chemistry Reference: 17α-[(ethoxycarbonyl)oxy]-11β-hydroxy-3-oxoandrosta-1,4-diene-17β-carboxylic ethoxycarboxylic anhydride(133991-62-5)
• EPA Substance Registry System: 17α-[(ethoxycarbonyl)oxy]-11β-hydroxy-3-oxoandrosta-1,4-diene-17β-carboxylic ethoxycarboxylic anhydride(133991-62-5)

Safety Data

• Hazardous Substances Data: 133991-62-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
17α-[(ethoxycarbonyl)oxy]-11β-hydroxy-3-oxoandrosta-1,4-diene-17β-carboxylic ethoxycarboxylic anhydride is used as an intermediate in the synthesis of corticosteroids for the treatment of various inflammatory and immunological disorders. Its structural diversity allows for the development of new corticosteroid drugs with improved pharmacological properties and reduced side effects.
Used in Research and Development:
In the field of medicinal chemistry, 17α-[(ethoxycarbonyl)oxy]-11β-hydroxy-3-oxoandrosta-1,4-diene-17β-carboxylic ethoxycarboxylic anhydride serves as a valuable research tool for studying the structure-activity relationships of corticosteroids. It can be used to investigate the effects of different functional groups on the biological activity and pharmacokinetics of these drugs, leading to the design of more effective and safer corticosteroid therapies.
Used in Quality Control and Impurity Profiling:
As a metabolite and impurity of Prednisolone, 17α-[(ethoxycarbonyl)oxy]-11β-hydroxy-3-oxoandrosta-1,4-diene-17β-carboxylic ethoxycarboxylic anhydride is used in the quality control and impurity profiling of corticosteroid drugs. Its analysis helps ensure the safety, efficacy, and purity of these medications, contributing to the overall quality of pharmaceutical products.

Upstream product

• 50-24-8 prednisolon 
• 37927-29-0 (1S,2R,10S,11S,14R,15S,17S)-14,17-dihydroxy-2,15-dimethyl-5-oxotetracyclo[8.7.0 0^2,7. 0^11,15]heptadeca-3,6-diene-14-carboxylic acid 
• 541-41-3 chloroformic acid ethyl ester 

Relevant articles and documents

A method for synthesizing loteprednol etabonate and a method for synthesizing intermediate (by machine translation)

The present invention provides a method of synthesizing loteprednol etabonate, comprises the following steps: step 1: to prednisolone as raw material preparation 11 β, 17 α - dihydroxy - 3 - oxo male steroid - 1, 4 - diene - 17 β - carboxylic acid; step 2: adopts the 11 β, 17 α - dihydroxy - 3 - oxo male steroid - 1, 4 - diene - 17 β - carboxylic acid preparation 17 α - ((ethoxy-formyl) oxy) - 11 β - hydroxy - 3 - oxo male steroid - 1, 4 - diene - 17 β - carboxylic acid ethyl carbonic anhydride; step 3: the 17 α - ((ethoxy-formyl) oxy) - 11 β - hydroxy - 3 - oxo male steroid - 1, 4 - diene - 17 β - carboxylic acid ethyl carbonic anhydride adding ethanol into sodium after a period of time by adding chlorine iodine methane then will be chlorine iodine methane. In step 3 can avoid the influence of the introduction of water to the intermediate. (by machine translation)

Loteprednol preparation method and ophthalmic composition of loteprednol

The present invention relates to a loteprednol preparation method and an ophthalmic composition of loteprednol, particularly to a loteprednol preparation method, which comprises: dissolving a raw material loteprednol in a first organic solvent to obtain a drug-containing solution, adding a second organic solvent to the obtained solution in a dropwise manner under stirring, continuously stirring, filtering, washing the filter cake by using the second organic solvent, and drying the obtained filter cake in a vacuum oven to obtain the product. The invention further provides a loteprednol bulk drug prepared according to the method, an ophthalmic pharmaceutical composition prepared by using the prepared loteprednol as a bulk drug, and uses of the prepared loteprednol in preparation of drugs for treatment or prevention of ocular inflammations or dry eye. The method of the present invention has excellent pharmaceutical properties, wherein the prepared bulk drug and the preparation have excellent stability.